23andMe Lays Off 40% of Staff, Shuts Drug Development Business
DNA-testing company 23andMe said on Monday that it was firing roughly 40% of its workforce, more than 200 people, as Chief Executive Anne Wojcicki seeks to stabilize her money-losing business. As part of the restructuring,
23andMe Lays Off 40 Percent of its Staff, Ends All Therapy Programs
As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.
23andMe is ending its cancer research program and slashing over 200 jobs
Though 23andMe says the restructuring plan will cost it around $12 million, it expects to save more than $35 million as a result, while “substantially” lowering operating expe
23andMe Slashes Workforce By 40%, Ends Therapeutic Programs
The therapeutic programs of 23andMe include an antibody that restores the ability of the immune system to kill cancer cells. It also has a therapeutic antibody that targets the ULBP6 gene, which suppresses the immune activity of cells.
23andMe to cut 40% of workforce, end therapeutics program
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday.
23andMe Lays Off 40% of Its Workforce as Company Spirals
The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire workforce, according to a press release Monday. The move is part of a restructuring that will see the company also halt the development of its therapeutics division which had been working on various potential medical treatments.
23andMe cuts 40% of its workforce, discontinues all therapy programs
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships,” said CEO Anne Wojcicki. The company said it is evaluating strategic ...
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.
23andMe announces workforce cut of 40% before the holidays
DNA site 23andMe is now announcing a big cut just before the holidays – the latest setback for the struggling South San Francisco startup.
23andMe warns of ‘substantial doubt’ over its survival without new funding
Genetics-testing company 23andMe has warned there is “substantial doubt” over its continued survival unless it raises new ...
FierceBiotech19h
23andMe shutters cancer drug research programs, lays off 40% of staff
We remain deeply grateful to the patients, investigators and study staff for their participation in our clinical trials,” ...
Richard Branson-backed 23andMe axes hundreds of jobs
Genetic testing company 23andMe, which is backed by Virgin billionaire Richard Branson’s VG Acquisition Corp, has revealed ...
DNA-testing site 23andMe to lay off 40% of its workers
The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for survival.
Pittsburgh Post-Gazette on MSN6d
Nila Bala: The risks of sharing your DNA with online companies aren’t a future concern. They’re here now
DNA commodification is no longer a future concern; it’s a present reality. Beyond charging users for their services, some ...
23andMe to reduce overall headcount by 40% of workforce
Holding “announced a business restructuring to streamline operations and reduce costs. In addition, 23andMe is discontinuing ...